Former Symphogen colleagues reunited in Norwegian biotech company

Former CEO of Symphogen Martin Olin, who has spearheaded Norwegian biotech company Bergenbio since September last year, can now greet a past colleague from Symphogen as Anders Tullgren steps in to chair Bergenbio.
Anders Tullgren and Martin Olin, past colleagues from their time at Symphogen, are reunited in the Norwegian biotech company Bergenbio, in which the former will be chair and the latter is CEO | Photo: Bergenbio / PR/Photographer: Nils Olav Mevatne - www.mevatne.no
Anders Tullgren and Martin Olin, past colleagues from their time at Symphogen, are reunited in the Norwegian biotech company Bergenbio, in which the former will be chair and the latter is CEO | Photo: Bergenbio / PR/Photographer: Nils Olav Mevatne - www.mevatne.no
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

CEO of Norwegian biotech company Bergenbio Martin Olin, who for a short time was a managing partner in venture capital firm Nordic Eye, will now be joined by a former colleague from his days at Symphogen, where Olin was in charge until October 2020 – few months after the company was sold for an estimated DKK 3bn (USD 455.7m) to French Servier.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading